Catabasis Pharmaceuticals Inc (NASDAQ:CATB)’s share price shot up 0% during trading on Tuesday . The stock traded as high as $1.77 and last traded at $1.60. 5,523,000 shares changed hands during mid-day trading, an increase of 331% from the average session volume of 1,280,352 shares. The stock had previously closed at $1.60.
Several brokerages have commented on CATB. Wedbush reiterated an “outperform” rating and issued a $4.00 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, December 15th. Zacks Investment Research upgraded shares of Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Thursday, November 16th. Finally, Citigroup upgraded shares of Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Monday, November 20th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $4.82.
The stock has a market cap of $36.93, a P/E ratio of -1.06 and a beta of 1.20.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.